Fine Print of Budget Deal Doesn't Bode Well for SGR OverhaulByTony Berberabe, MPH,Mary K. CaffreyFebruary 12th 2014
Immunotherapy in Cancer Care: Understanding the Impact of Shifting Treatment Paradigms in the Managed Care SettingByFebruary 12th 2014
Post Marketing Research No Longer an Afterthought With Targeted TherapiesByMary K. CaffreyFebruary 12th 2014
Adjuvant Pre- or Post-Operative Chemotherapy Does Not Improve Survival in Rectal CancerBySurabhi Dangi-Garimella, PhDFebruary 12th 2014
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than EverByMary K. CaffreyFebruary 12th 2014
As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical IssuesByMary K. CaffreyFebruary 12th 2014
When Less Is More: Results Herald 'Paradigm Shift' in Treating Newly Diagnosed Multiple Myeloma PatientsByMary K. CaffreyFebruary 12th 2014
In Cancer and Beyond, Washington State Making the Transition to Value- Based CareByMary K. CaffreyFebruary 11th 2014
Sorting Out What Makes Sense in Diagnosing, Treating Prostate CancerByNicole BeaginFebruary 11th 2014
Defining, Measuring, and Paying for the Work of Oncology Patient NavigatorsByPeter PageFebruary 11th 2014
A Test to Prevent Repeat Prostate Biopsies? Perhaps, if the Bar of 'Clinical Utility' Can Be MetByMary K. CaffreyFebruary 11th 2014
